Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteersSAAH, Alfred J; WINCHELL, Gregory A; NESSLY, Michael L et al.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 10, pp 2710-2715, issn 0066-4804Article

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionCOOPER, David A; STEIGBIGEL, Roy T; SCHECHTER, Mauro et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 355-365, issn 0028-4793, 11 p.Article

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairmentTHAL, Leon J; FERRIS, Steven H; REINES, Scott A et al.Neuropsychopharmacology (New York, NY). 2005, Vol 30, Num 6, pp 1204-1215, issn 0893-133X, 12 p.Article

Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trialsCOPLAN, Paul M; NIKAS, Alexander A; LEAVITT, Randi Y et al.AIDS (London). 2001, Vol 15, Num 12, pp 1584-1586, issn 0269-9370Article